Ensysce Biosciences Inc. (ENSC)
| Bid | 2.06 |
| Market Cap | 4.98M |
| Revenue (ttm) | 2.81M |
| Net Income (ttm) | -6.82M |
| EPS (ttm) | 110.31 |
| PE Ratio (ttm) | 0.02 |
| Forward PE | -41.04 |
| Analyst | n/a |
| Ask | 2.13 |
| Volume | 9,437 |
| Avg. Volume (20D) | 1,742,600 |
| Open | 2.09 |
| Previous Close | 2.15 |
| Day's Range | 2.07 - 2.14 |
| 52-Week Range | 1.62 - 14.67 |
| Beta | 0.98 |
About ENSC
undefined
6 days ago · accessnewswire.com
Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025~ Pain Management, RE-Invented: A New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / June 11, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharm...
1 month ago · accessnewswire.com
Ensysce Biosciences Reports First Quarter 2025 Financial ResultsReceives U.S. Patent for Groundbreaking Treatment for Opioid Use Disorder Clinical Trial on Novel Analgesic, PF614-MPAR, Demonstrates Overdose Protection SAN DIEGO, CA / ACCESS Newswire / May 13, 2025...
1 month ago · accessnewswire.com
Ensysce Biosciences Bolsters Management Team with Regulatory Expert~ Advanced Preparation for New Drug Application ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical...
1 month ago · accessnewswire.com
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross ProceedsSAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain reli...
1 month ago · accessnewswire.com
Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder~ Applies TAAP and MPAR Technology to Produce Novel OUD Treatments ~ ~ Prioritizes Safety and Tolerability for OUD Patients ~ SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, In...
2 months ago · accessnewswire.com
Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study~ Additional Evidence of PF614-MPAR Overdose Protection after Completion of Part 1 of Clinical Study ~ SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensy...
